(Q34175502)

31 July 2017

1 reference

title

Low-dose oral contraceptives: health consequences of discontinuation (English)

1 reference

31 July 2017

Ansbacher R

1

1 reference

31 July 2017

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

62

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

285-288

1 reference

What do women use when they stop using the pill?

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Prevention and medical management of unwanted pregnancy: the physician's role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Public-sector savings resulting from expenditures for contraceptive services

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Compliance and oral contraceptives: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Contraceptive failure in the United States: a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Minimizing the problem of poor compliance in adolescents. Clinical experience with a modern low-dose gestodene-containing oral contraceptive.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Interchangeability of low-dose oral contraceptives. Are current bioequivalent testing measures adequate to ensure therapeutic equivalency?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Generic drugs and the prescribing physician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 mic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

Oral contraceptives and cycle control: a critical review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900179-7

10.1016/S0010-7824(00)00179-7

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference